Literature DB >> 25795305

Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?

Thale Kristin Olsen1, Ioannis Panagopoulos1, Torstein R Meling1, Francesca Micci1, Ludmila Gorunova1, Jim Thorsen1, Bernt Due-Tønnessen1, David Scheie1, Marius Lund-Iversen1, Bård Krossnes1, Cathrine Saxhaug1, Sverre Heim1, Petter Brandal1.   

Abstract

BACKGROUND: We have previously characterized 19 ependymal tumors using Giemsa banding and high-resolution comparative genomic hybridization. The aim of this study was to analyze these tumors searching for fusion genes.
METHODS: RNA sequencing was performed in 12 samples. Potential fusion transcripts were assessed by seed count and structural chromosomal aberrations. Transcripts of interest were validated using fluorescence in situ hybridization and PCR followed by direct sequencing.
RESULTS: RNA sequencing identified rearrangements of the anaplastic lymphoma kinase gene (ALK) in 2 samples. Both tumors harbored structural aberrations involving the ALK locus 2p23. Tumor 1 had an unbalanced t(2;14)(p23;q22) translocation which led to the fusion gene KTN1-ALK. Tumor 2 had an interstitial del(2)(p16p23) deletion causing the fusion of CCDC88A and ALK. In both samples, the breakpoint of ALK was located between exons 19 and 20. Both patients were infants and both tumors were supratentorial. The tumors were well demarcated from surrounding tissue and had both ependymal and astrocytic features but were diagnosed and treated as ependymomas.
CONCLUSIONS: By combining karyotyping and RNA sequencing, we identified the 2 first ever reported ALK rearrangements in CNS tumors. Such rearrangements may represent the hallmark of a new entity of pediatric glioma characterized by both ependymal and astrocytic features. Our findings are of particular importance because crizotinib, a selective ALK inhibitor, has demonstrated effect in patients with lung cancer harboring ALK rearrangements. Thus, ALK emerges as an interesting therapeutic target in patients with ependymal tumors carrying ALK fusions.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  RNA sequencing; anaplastic lymphoma kinase; chromosomal aberrations; ependymoma; fusion genes

Mesh:

Substances:

Year:  2015        PMID: 25795305      PMCID: PMC4578580          DOI: 10.1093/neuonc/nov039

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  48 in total

1.  Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.

Authors:  D C Stylianou; A Auf der Maur; D P Kodack; R T Henke; S Hohn; J A Toretsky; A T Riegel; A Wellstein
Journal:  Oncogene       Date:  2009-07-27       Impact factor: 9.867

2.  Identification of the TAF15-ZNF384 fusion gene in two new cases of acute lymphoblastic leukemia with a t(12;17)(p13;q12).

Authors:  Kaja Beate Nyquist; Jim Thorsen; Bernward Zeller; Alf Haaland; Gunhild Trøen; Sverre Heim; Francesca Micci
Journal:  Cancer Genet       Date:  2011-03

3.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Authors:  Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

4.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

Review 5.  ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages.

Authors:  Adrian Mariño-Enríquez; Paola Dal Cin
Journal:  Cancer Genet       Date:  2013-10-03

Review 6.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

Review 7.  The impact of translocations and gene fusions on cancer causation.

Authors:  Felix Mitelman; Bertil Johansson; Fredrik Mertens
Journal:  Nat Rev Cancer       Date:  2007-03-15       Impact factor: 60.716

8.  Current treatment options for pediatric and adult patients with ependymoma.

Authors:  Karen D Wright; Amar Gajjar
Journal:  Curr Treat Options Oncol       Date:  2012-12

9.  Transcriptome sequencing to detect gene fusions in cancer.

Authors:  Christopher A Maher; Chandan Kumar-Sinha; Xuhong Cao; Shanker Kalyana-Sundaram; Bo Han; Xiaojun Jing; Lee Sam; Terrence Barrette; Nallasivam Palanisamy; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-01-11       Impact factor: 49.962

10.  Genomic characterization of ependymomas reveals 6q loss as the most common aberration.

Authors:  Thale Kristin Olsen; Ludmila Gorunova; Torstein R Meling; Francesca Micci; David Scheie; Bernt Due-Tønnessen; Sverre Heim; Petter Brandal
Journal:  Oncol Rep       Date:  2014-06-16       Impact factor: 3.906

View more
  14 in total

1.  Targetable molecular alterations in congenital glioblastoma.

Authors:  Ahmed Gilani; Andrew Donson; Kurtis D Davies; Susan L Whiteway; Jessica Lake; John DeSisto; Lindsey Hoffman; Nicholas K Foreman; B K Kleinschmidt-DeMasters; Adam L Green
Journal:  J Neurooncol       Date:  2019-12-24       Impact factor: 4.130

Review 2.  2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist.

Authors:  Cillian McNamara; Kshitij Mankad; Stefanie Thust; Luke Dixon; Clara Limback-Stanic; Felice D'Arco; Thomas S Jacques; Ulrike Löbel
Journal:  Neuroradiology       Date:  2022-07-22       Impact factor: 2.995

3.  ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3.

Authors:  Mengnan Hu; Ruoxuan Bao; Miao Lin; Xiao-Ran Han; Ying-Jie Ai; Yun Gao; Kun-Liang Guan; Yue Xiong; Hai-Xin Yuan
Journal:  Oncogene       Date:  2022-09-05       Impact factor: 8.756

4.  Recurrent fusion of the genes FN1 and ALK in gastrointestinal leiomyomas.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Marius Lund-Iversen; Ingvild Lobmaier; Bodil Bjerkehagen; Sverre Heim
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

Review 5.  An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.

Authors:  Alvaro Lassaletta; Michal Zapotocky; Eric Bouffet; Cynthia Hawkins; Uri Tabori
Journal:  Childs Nerv Syst       Date:  2016-09-20       Impact factor: 1.475

6.  ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

Authors:  Jeffrey S Ross; Siraj M Ali; Omotayo Fasan; Jared Block; Sumanta Pal; Julia A Elvin; Alexa B Schrock; James Suh; Sahar Nozad; Sungeun Kim; Hwa Jeong Lee; Christine E Sheehan; David M Jones; Jo-Anne Vergilio; Shakti Ramkissoon; Eric Severson; Sugganth Daniel; David Fabrizio; Garrett Frampton; Vince A Miller; Philip J Stephens; Laurie M Gay
Journal:  Oncologist       Date:  2017-10-27

7.  Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.

Authors:  Matthew Clarke; Alan Mackay; Britta Ismer; Jessica C Pickles; Ruth G Tatevossian; Scott Newman; Tejus A Bale; Iris Stoler; Elisa Izquierdo; Sara Temelso; Diana M Carvalho; Valeria Molinari; Anna Burford; Louise Howell; Alex Virasami; Amy R Fairchild; Aimee Avery; Jane Chalker; Mark Kristiansen; Kelly Haupfear; James D Dalton; Wilda Orisme; Ji Wen; Michael Hubank; Kathreena M Kurian; Catherine Rowe; Mellissa Maybury; Stephen Crosier; Jeffrey Knipstein; Ulrich Schüller; Uwe Kordes; David E Kram; Matija Snuderl; Leslie Bridges; Andrew J Martin; Lawrence J Doey; Safa Al-Sarraj; Christopher Chandler; Bassel Zebian; Claire Cairns; Rachael Natrajan; Jessica K R Boult; Simon P Robinson; Martin Sill; Ira J Dunkel; Stephen W Gilheeney; Marc K Rosenblum; Debbie Hughes; Paula Z Proszek; Tobey J Macdonald; Matthias Preusser; Christine Haberler; Irene Slavc; Roger Packer; Ho-Keung Ng; Shani Caspi; Mara Popović; Barbara Faganel Kotnik; Matthew D Wood; Lissa Baird; Monika Ashok Davare; David A Solomon; Thale Kristin Olsen; Petter Brandal; Michael Farrell; Jane B Cryan; Michael Capra; Michael Karremann; Jens Schittenhelm; Martin U Schuhmann; Martin Ebinger; Winand N M Dinjens; Kornelius Kerl; Simone Hettmer; Torsten Pietsch; Felipe Andreiuolo; Pablo Hernáiz Driever; Andrey Korshunov; Lotte Hiddingh; Barbara C Worst; Dominik Sturm; Marc Zuckermann; Olaf Witt; Tabitha Bloom; Clare Mitchell; Evelina Miele; Giovanna Stefania Colafati; Francesca Diomedi-Camassei; Simon Bailey; Andrew S Moore; Timothy E G Hassall; Stephen P Lowis; Maria Tsoli; Mark J Cowley; David S Ziegler; Matthias A Karajannis; Kristian Aquilina; Darren R Hargrave; Fernando Carceller; Lynley V Marshall; Andreas von Deimling; Christof M Kramm; Stefan M Pfister; Felix Sahm; Suzanne J Baker; Angela Mastronuzzi; Andrea Carai; Maria Vinci; David Capper; Sergey Popov; David W Ellison; Thomas S Jacques; David T W Jones; Chris Jones
Journal:  Cancer Discov       Date:  2020-04-01       Impact factor: 39.397

Review 8.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

9.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.

Authors:  Ana S Guerreiro Stucklin; Scott Ryall; Kohei Fukuoka; Michal Zapotocky; Alvaro Lassaletta; Christopher Li; Taylor Bridge; Byungjin Kim; Anthony Arnoldo; Paul E Kowalski; Yvonne Zhong; Monique Johnson; Claire Li; Arun K Ramani; Robert Siddaway; Liana Figueiredo Nobre; Pasqualino de Antonellis; Christopher Dunham; Sylvia Cheng; Daniel R Boué; Jonathan L Finlay; Scott L Coven; Inmaculada de Prada; Marta Perez-Somarriba; Claudia C Faria; Michael A Grotzer; Elisabeth Rushing; David Sumerauer; Josef Zamecnik; Lenka Krskova; Miguel Garcia Ariza; Ofelia Cruz; Andres Morales La Madrid; Palma Solano; Keita Terashima; Yoshiko Nakano; Koichi Ichimura; Motoo Nagane; Hiroaki Sakamoto; Maria Joao Gil-da-Costa; Roberto Silva; Donna L Johnston; Jean Michaud; Bev Wilson; Frank K H van Landeghem; Angelica Oviedo; P Daniel McNeely; Bruce Crooks; Iris Fried; Nataliya Zhukova; Jordan R Hansford; Amulya Nageswararao; Livia Garzia; Mary Shago; Michael Brudno; Meredith S Irwin; Ute Bartels; Vijay Ramaswamy; Eric Bouffet; Michael D Taylor; Uri Tabori; Cynthia Hawkins
Journal:  Nat Commun       Date:  2019-09-25       Impact factor: 14.919

Review 10.  Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.

Authors:  Neetha Nanoth Vellichirammal; Nagendra K Chaturvedi; Shantaram S Joshi; Donald W Coulter; Chittibabu Guda
Journal:  Cancer Lett       Date:  2020-11-25       Impact factor: 9.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.